Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)

19 augusti 2022 uppdaterad av: Duke University

Pathways to Cardiovascular Disease Prevention and Impact of Specialty Referral in Underrepresented Racial/Ethnic Minorities With HIV (Coordinating Center)

The goal of this research is to generate evidence-based recommendations for the management of cardiovascular disease (CVD) risk in People Living with HIV (PLWH). The overall objectives of this application are to demonstrate the effect of cardiology referral on CVD outcomes in a racially/ethnically diverse cohort of PLWH, and to generate qualitative data with which to develop of a future intervention. Our central hypothesis is that cardiology referral reduces incident CVD events in underrepresented racial/ethnic minority (URM) populations with HIV compared to nonreferral. Our hypothesis has been formulated based on our own work identifying that race and provider specialty impact cardiovascular risk management. The rationale for our research is that, once it is known how URM populations with HIV access cardiology referrals, and the impact on CVD outcomes, an intervention can be appropriately designed resulting in new and innovative approaches to the management of URM PLWH at elevated CVD risk.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

Aim 1. To identify factors associated with cardiology referral in under-represented racial and ethnic minority (URM) populations with HIV and elevated cardiovascular risk Aim 2. To evaluate the association between cardiology referral and CVD outcomes in under-represented racial and ethnic populations with HIV and elevated cardiovascular risk Sub-Aim 2a. To evaluate the association between cardiology referral and guideline-based CVD prevention measures in URM populations with HIV and elevated CVD risk

Note: Aims 1 and 2-retrospective analysis with anticipated 8000 EHR records to be reviewed.

Aim 3. To identify facilitators and barriers to optimal CVD prevention

Studietyp

Observationell

Inskrivning (Faktisk)

57

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27707
        • Duke University
      • Winston-Salem, North Carolina, Förenta staterna, 27157
        • Wake Forest University Health Sciences
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • University Hospitals Cleveland Medical Center
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Medical University of South Carolina
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37232-2582
        • Vanderbilt University Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

N/A

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Aims 1 and 2 not recruiting patients

Aims 3 population of interest:

  1. Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
  2. Documented evidence of HIV positive status (HIV positive diagnosis and prescription of antiretroviral therapy (ART));

Beskrivning

Aims 1 and 2 are not recruiting as retrospective review of electronic health records.

Aims 1 and 2 Inclusion Criteria:

Patient health records may be accessed from subjects who meet the following criteria:

  1. Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
  2. Documented evidence of HIV positive status (HIV positive diagnosis (ICD10 codes B20-B24, or ICD9 codes 042, V08) and prescription of antiretroviral therapy (ART));
  3. Documented evidence of elevated AtheroSclerotic CardioVascular Disease risk (ACC/AHA ASCVD 10 year risk ≥5%24, or Framingham Cardiovascular Disease 10 year risk ≥5%25) after HIV diagnosis. The date when the patient first meets either of these CVD risk thresholds and with 1 prior encounter not having CVD risk score defines the index time-point for Aim 1 of this study. These risk calculations depend on sex, age, body mass index, diabetes, current smoking, total cholesterol, HDL cholesterol, systolic blood pressure, and treatment for hypertension (defined from diagnosis codes). If cholesterol measures are not available, then body mass index may be used in place of lipids in the Framingham risk calculation; NOTE: must have a prior encounter within 365 days within health system prior to index
  4. Presence of a modifiable risk factor: hypertension, diabetes, elevated total cholesterol, elevated LDL cholesterol and/or tobacco use.

Aims 1 and 2 Exclusion criteria:

  1. Age <18 years of age or >99 years of age at index event;
  2. Pre-existing ASCVD prior to index event, including a previous diagnosis of any acute myocardial infarction, heart failure, acute coronary syndromes, stable or unstable angina, arterial revascularization (includes coronary arterial or peripheral), stroke, transient ischemic attack or peripheral arterial disease presumed to be of atherosclerotic origin determined by ICD codes;
  3. Encounter with cardiology specialist within 1 year prior to index
  4. Evidence of ART for pre-exposure prophylaxis (i.e., Truvada [emtricitabine/tenofovir disoproxil fumarate] or post-exposure prophylaxis (e.g., Truvada plus raltegravir) without HIV diagnosis.

Aim 3 Inclusion Criteria:

  • Patients:

    1. under-represented racial and ethnic minority (URM) populations with HIV > 40 years of age, with
    2. a modifiable risk factor for Cardiovascular disease (CVD) (such as hypertension, diabetes, elevated total cholesterol, high LDL cholesterol, or currently use tobacco), and/or known CVD
  • Providers

    1. HIV providers will include infectious disease physicians, Internists or advance practice practitioners who report having seen > 1 person living with HIV under their care in the last 6 months; AND
    2. Cardiology providers (physicians or advance practice providers) will be required to have taken care of at least 1 HIV-positive patient in the past 3 years;

Aim 3 Exclusion Criteria:

  • Patients

    1. Unwilling or unable to provide oral informed consent;
    2. Unable to perform an interview in English;
    3. Diminished capacity to give oral consent;
    4. Unwilling to be interviewed.
  • Providers

    1. Unable to perform an interview in English;
    2. Unwilling to be interviewed.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of patients with referral to a cardiology specialist (primary outcome for Aim 1)
Tidsram: 6 months from the date when patient met eligibility criteria for referral
A binary variable, with 'yes' defined if there is documented evidence that a referral is made within 6 months of becoming eligible by CVD risk score and kept within 3 months of referral, and 'no' otherwise. Cardiology referrals with kept appointments will be ascertained from electronic health record data.
6 months from the date when patient met eligibility criteria for referral
Proportion of patients with blood pressure control (primary outcome for Aim 2)
Tidsram: Longitudinal evaluation during 5 years of follow up.
Blood pressure control will be defined based on prevailing guidelines during the study period (blood pressure <140/90 mmHg) and will be evaluated based on blood pressures recorded in electronic health record data.
Longitudinal evaluation during 5 years of follow up.
Proportion of patients with Cholesterol control (co-primary outcome for Aim 2)
Tidsram: Longitudinal evaluation during 5 years of follow up.
Cholesterol control will be defined based on prevailing guidelines during the study period and will be evaluated based on cholesterol laboratory measures recorded in electronic health record data.
Longitudinal evaluation during 5 years of follow up.
Patient perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Tidsram: Approximately 60 minutes
Qualitative information will be assessed from semi-structured interviews conducted with participating patients
Approximately 60 minutes
Provider perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Tidsram: Approximately 60 minutes
Qualitative information will be assessed from semi-structured interviews conducted with participating healthcare providers
Approximately 60 minutes

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of major adverse cardiovascular event, myocardial infarction (secondary outcome for Aim 2)
Tidsram: 5 years
Incidence of first major adverse cardiovascular event (composite of cardiovascular death and myocardial infarction) will be determined from diagnosis and/or procedure codes from electronic health record data and a query of the National Death Index (Plus).
5 years
Incidence of Stroke (secondary outcome for Aim 2)
Tidsram: 5 years
Incidence of first stroke event will be determined from diagnosis and/or procedure codes from electronic health record data.
5 years
Incidence of All-cause death (secondary outcome for Aim 2)
Tidsram: 5 years
Incidence of all-cause death will be determined from electronic health record data and a query of the National Death Index.
5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Gerald Bloomfield, MD, Duke Health

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 oktober 2019

Primärt slutförande (Faktisk)

30 juli 2022

Avslutad studie (Faktisk)

30 juli 2022

Studieregistreringsdatum

Först inskickad

2 juli 2019

Först inskickad som uppfyllde QC-kriterierna

17 juli 2019

Första postat (Faktisk)

18 juli 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 augusti 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

19 augusti 2022

Senast verifierad

1 augusti 2022

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • Pro00101104
  • 1R01MD013493-01 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

3
Prenumerera